Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Tecentriq | Atezolizumab | Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Probuphine | buprenorphine hydrochloride | Opioid drug dependence, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
| Juluca | Dolutegravir rilpivirine | HIV infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Monoprost | latanoprost | glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ocrevus | ocrelizumab | Primary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kanuma | sebelipase alfa | Lysosomal acid lipase deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lonsurf | Trifluridine and Tipiracil | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Repatha | Evolocumab | Primary hyperlipidemia and mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Faslodex | Fulvestrant | Locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 19, 2024